miércoles, 10 de febrero de 2016

Ixazomib Citrate - National Cancer Institute

Ixazomib Citrate - National Cancer Institute



National Cancer Institute



pharmacist holding drug vial

New Drug for Multiple Myeloma

A new summary about the drug ixazomib citrate. It was recently approved by the Food and Drug Administration (FDA) to treat multiple myeloma in patients who have already received at least one other treatment.

Ixazomib Citrate

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
 (ik-SA-zoh-mib SIH-trayt)
This page contains brief information about ixazomib citrate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s)
Ninlaro
FDA Approved
Yes

Use in Cancer

Ixazomib citrate is approved to be used with lenalidomide and dexamethasone to treat:
  • Multiple myeloma in patients who have already received at least one other type of treatment.
Ixazomib citrate is also being studied in the treatment of other types of cancer.

More About Ixazomib Citrate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Targeted Cancer Therapies - Information about the use of this drug to treat cancer.

Clinical Trials Accepting Patients

Find Clinical Trials for Ixazomib Citrate - Check for trials from NCI's list of cancer clinical trials now accepting patients.

No hay comentarios:

Publicar un comentario